Audit of Intangible Assets Assignment
Audit of Intangible Assets Assignment
The cost of buildings used for R&D can be capitalized if they directly support project development. The acquisition cost is capitalized initially, and depreciation recognized over its useful life aligns with R&D cycle support. For instance, the cost in Source 2 is capitalized as it prepares the groundwork for potential innovations, directly impacting future capabilities. Depreciation affects net income and asset value consistently, ensuring regulatory compliance .
Routine changes don't qualify for R&D capitalization, unlike groundbreaking developments that can generate future benefits and should be capitalized. Proper differentiation affects asset valuation and income statement, influencing financial analysis. For Jimar Co., costs like routine tooling or seasonal design changes aren’t capitalized, impacting short-term expense versus long-term asset creation .
R&D costs are recorded based on whether they provide future economic benefits. Costs such as those aimed at obtaining new knowledge, developing a prototype, and testing for safety are part of R&D expense. Routine or commercial production related costs and marketing are expensed differently. Jimar Co. should record costs like prototype development and safety testing, while marketing expenses would not be capitalized as R&D .
Prepaid rent is typically recorded as an asset on the balance sheet and amortized over time. For Faith Corporation, with a 2-year leasehold, the prepaid rent is divided over the lease term. By the end of 2023, one year has been amortized, so half the original prepaid amount remains unamortized, shown as an asset. The remaining balance would be 42,000 in this context .
Karen Inc. should record the patent at the fair value of the shares exchanged, as the shares are easier to value given their market price. On February 14, 2024, Karen exchanged 2,000 treasury shares with a par value but were valued at the market price of P110 per share, making the patent value recorded P220,000. This reflects the fair value principle, prioritizing the market value of the exchanged goods .
Capitalizing excess earnings involves calculating the present value of an entity's excess returns (actual returns above the normal rate of return) using a capitalization rate. For Joy Company, excess earnings are those above 20% of average net assets. With goodwill measured by capitalizing these excess earnings at 25%, the difference informs potential goodwill or a premium paid above the tangible net assets. It's a method to estimate the value of intangible benefits, such as reputation .
The useful life of an intangible asset directly impacts its amortization schedule. For Rex Company, initial amortization was calculated based on a 10-year useful life for the original patent. Subsequent acquisitions and legal outcomes affected this calculation, extending the useful life but also introducing losses when a legal defense failed. Accurate estimation of useful life ensures correct expense recognition and prevents misstatement of asset value .
Costs are capitalized if they are expected to generate future economic benefits, such as development costs leading to patents or proprietary formulas. The cost of developing a secret formula, like Faith's P225,000 incurred, could be capitalized if it results in a patent or proprietary advantage. Determining factors include technical feasibility, potential to market, and identifiable future benefits. Otherwise, these costs would be expensed as incurred .
A failed legal defense typically results in a write-off of the associated intangible asset, reflecting its impaired value. In Rex Company's case, the unsuccessful defense cost of P100,000 necessitated writing off this amount as a loss. This action aligns with recognizing reduced utility or protection of the patent, hence needing an adjustment in the financial statements to reflect the diminished economic benefit .
Inaccurate amortization affects reported earnings, asset values, and net income. If Rex Company fails to recognize correct amortization, this misstates patent asset value and inflates financial health. Amortization spreads cost over its useful life, so underreporting delays expense recognition, impacting financial ratios, tax liabilities, and investor decisions. Such discrepancies necessitate restatements impacting stakeholders' trust .